Olfactory Training As a Treatment for Olfactory Dysfunction Post COVID-19
OTTODC19
L'entraînement Olfactif Comme Traitement De La Dysfonction Olfactive Post COVID-19
1 other identifier
interventional
70
1 country
1
Brief Summary
Olfactory dysfunction is a defining symptom of COVID-19 infection. Studies have demonstrated improved olfaction in patients with post infectious olfactory dysfunction after an olfactory training (OT). The aim of this study is to assess the clinical outcomes of olfactory training (12 weeks) therapy in the treatment of persistent olfactory dysfunctions after COVID-19. Specially, we aim to compare the effectiveness of two different olfactory training (different odors). A group will train themselves with 4 scents (rose, orange, clove and eucalyptus) and another group with 4 different scents (cheese, coffee, strawberries and lemon). Olfaction sensory evaluation will be performed by using different olfaction tests (Sniffin' Sticks and UPSIT) and complete questionnaires to assess olfactory perception and particularly parosmia and phantosmia.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started May 2022
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 19, 2022
CompletedFirst Posted
Study publicly available on registry
May 20, 2022
CompletedStudy Start
First participant enrolled
May 31, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2025
CompletedDecember 17, 2024
December 1, 2024
3.3 years
May 19, 2022
December 11, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (5)
Changes from baseline in olfactory score on the University of Pennsylvania Identification Test (UPSIT) [ Time Frame: Measurement will be taken at time zero (pre-intervention) and 12 weeks (post-intervention)
The UPSIT includes 4 odor-impregnated booklets that contain 10 forced-choice multiple choice questions each for participants to scratch-and-sniff to identify various odors and is a commercially available test. Normosmia is defined as ≥34 for males and ≥35 for females, and a change of 4 points or more from baseline indicates a clinically meaningful result.
Measurement will be taken at time zero (pre-intervention) and 12 weeks (post-intervention)
Changes from baseline in olfactory score on the Sniffin's Sticks test
Sniffin' Sticks test and Taste strips: Sniffin' Sticks test (Burghardt®, Wedel, Germany) is a psychophysical test. It allows semi-objective assessment of the patient's olfactory performance by means of 3 subtests: threshold test, identification test and discrimination test. The Sniffin' Sticks Olfactory Test Kits contain pen like bodies as, for example, in pens used to write on flipcharts or whiteboards.These pen-like bodies, however, contain a fibre stick which is filled with scents. For testing, the cap should be removed so the patient can smell on the tip of the pen.
Measurement will be taken at time zero (pre-intervention) and 12 weeks (post-intervention)
n-house test for chemosensory dysfunction (TMSC)
The TMSC is a 55-item questionnaire evaluating the three chemical senses: olfaction, taste and the trigeminal sense. First, questions with a 10-point visual analog scale make a subjective self-assessment of each of the three senses. Multiple-choice questions establish the precise characteristics of the dysfunctions of each of the senses if they are present. Secondly, a psychophysical test is administered remotely using substances typical of North American cuisines. Substances are first sniffed (peanut butter, jam, vinegar, coffee) then tasted (peanut butter, jam, salt water (1 tsp/250mL), sugar water (3 tsp/250mL)). The perceived intensity of each of the substances is reported each time on a visual analogue scale of 10 points.
Measurement will be taken at time zero (pre-intervention) and 12 weeks (post-intervention)
Parosmia and phantosmia assessment test
This test has a first part with four questions that aim to assess the presence of parosmia or phastosmia. Patients who have reported parosmia or phantosmia will be asked to complete a second part with six questions focusing on the quality of their olfactory distortion.
Measurement will be taken at time zero (pre-intervention) and 12 weeks (post-intervention)
The abridged version of the Questionnaire of Olfactory Disorders - Negative Statements (sQOD-NS)
The sQOD-NS is a validated questionnaire that measures the quality of life specific to olfactory functions. The questionnaire measures 7 items with a 4-point Likert scale.
Measurement will be taken at time zero (pre-intervention) and 12 weeks (post-intervention)
Secondary Outcomes (1)
Nasal Obstruction Symptom Evaluation (NOSE)
Measurement will be taken at time zero (pre-intervention)
Study Arms (2)
Chemosensory training group 1
EXPERIMENTALFor 12 weeks, morning and evening, smell four odors namely eucalyptol, phenyl ethanol, Orange, and eugenol, for a total of five minutes per session.
Chemosensory training group 2
EXPERIMENTALFor 12 weeks, morning and evening, smell four odors namely coffee aroma, cheese aroma, strawberries, and limon, for a total of five minutes per session.
Interventions
For 12 weeks, morning and evening, smell four different odors or four odorless substances for a total of five minutes per session.
Eligibility Criteria
You may qualify if:
- Patient diagnosed positive for COVID-19 with persistent olfactory dysfunction
- Willing and able to provide written informed consent
- Understand and read the French language
- Have an internet connection and a working email address
You may not qualify if:
- Anosmia and hyposmia pre-covid-19
- Be known chronic rhinosinusitis with or without nasal polyposis
- Have received radiotherapy or chemotherapy for Head and Neck Tumors
- Have a diagnosis of Alzheimer's, Parkinson's, multiple sclerosis or any other neurodegenerative disease 5. Have a brain tumor or ENT diagnosis 6. History of naso-sinus surgery; 7. History of traumatic brain injury
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Université du Québec à Trois-Rivières
Trois-Rivières, Quebec, G8Z 4M3, Canada
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Johannes A Frasnelli, PhD
Université du Québec à Trois-Rivières
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 19, 2022
First Posted
May 20, 2022
Study Start
May 31, 2022
Primary Completion
September 1, 2025
Study Completion
September 1, 2025
Last Updated
December 17, 2024
Record last verified: 2024-12